Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept, while establishing R&D collaborations with select partners to improve products in their pipelines.
Funding Rounds (6) - $114.24MUpdate
Current Team (8)Update
|Jun 7, 2016||Med City News - Longitude Capital raises $525M for third fund spanning early to late stage medtech investments|
|Jun 2, 2016||Market Wired - Top - Keynote Speaker and Final Agenda Announced for Targeting Ocular Disorders 2016|
|Apr 14, 2016||Venture Capital News - Venture Capital Database 2016 Now Available!|
|Apr 13, 2016||talent4boards.com - Kala Pharmaceuticals adds Gregory Grunberg and Chen Yu to its Board along with closing $68m Series C financing led by Longitude Capital|
|Apr 13, 2016||BioSpace - Massachusetts' Mucus Penetrating Eye Disease Firm Kala Pharma Raises $68 Million|
|Apr 13, 2016||Xconomy - Kala Pharma Nabs $68M, Crossover Backers for Eye Drug Push|
|Dec 8, 2015||PRNewswire All - Pulmatrix Appoints Mark Iwicki Chairman of the Board|
|Dec 4, 2015||Business Wire - Research and Markets: Diabetic Macular Edema Pipeline Review, H2 2015|
100 Beaver St.
Waltham, MA 02453
135 Beaver St., Suite 309
Waltham, MA 02452